

Locally manufactured *versus* commercial CAR T therapy for large B-cell lymphoma: a multicenter propensity score-matched analysis

Ronit Marcus,^{1,2*} Abraham Avigdor,^{1,2*} Uri Greenbaum,³ Samantha Brown,⁴ Shalev Fried,^{2,5} Noa Golan-Accav,^{1,2} Noga Shem-Tov,^{1,2} Ronit Yerushalmi,^{1,2} Ivetta Danylesko,^{1,2} Elad Jacoby,^{1,2} Arnon Nagler,^{1,2} Avichai Shimoni,^{1,2} Orit Itzhaki,^{1,2} Jonathan Esenstein,⁶ Ori Ben Valid,^{1,2} Annamaria Ballweg,^{7,8} Xavier Deschênes-Simard,^{7,8} Efrat Luttwak,^{7,8} Gunjan Shah,^{7,8} Michael Scordo,^{7,8} Parastoo Dahi,^{7,8} Miguel-Angel Perales,^{7,8} Tsila Zuckerman,^{9,10} Sean M. Devlin,⁴ Dana Yehudai-Ofir,^{9,10} Hazim Khatib,^{9,10} Nivin Shibly,⁹ Roni Shouval^{7,8#} and Ofrat Beyar-Katz^{9,10#}

¹Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel HaShomer, Israel; ²Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel; ³Department of Hematology, Soroka University Medical Center and Faculty of Health and Science, Ben Gurion University of the Negev, Beer Sheva, Israel; ⁴Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁵The Goldschleger Eye Institute, Sheba Medical Center, Tel HaShomer, Israel; ⁶Advanced Biotherapy Center, Sheba Medical Center, Tel Hashomer, Israel; ⁷Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁸Department of Medicine, Weill Cornell Medical College, New York, NY, USA; ⁹Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel and ¹⁰Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

*RM and AA contributed equally as first authors.

#RS and OB-K contributed equally as senior authors.

Correspondence: R. Shouval
shouvalr@mskcc.org

Received: June 11, 2025.

Accepted: December 16, 2025.

Early view: December 24, 2025.

<https://doi.org/10.3324/haematol.2025.288419>

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license



Supplemental Table 1: Frequency of CAR-T cell therapy product by site

Characteristic	MSKCC, N = 128 [†]	Rambam Health Care Campus, N = 19 [†]	Sheba Medical Center, N = 183 [†]
CAR-T product			
Axicabtagene ciloleucel	71 (55%)	10 (53%)	51 (28%)
Tisagenlecleucel	57 (45%)	9 (47%)	38 (21%)
Sheba POC anti CD19	0 (0%)	0 (0%)	94 (51%)
[†] n (%)			

Supplemental Table 2: Disease response at day 100 by CAR-T cell therapy product

Characteristic	Axicabtagene ciloleuce, N = 132 [†]	Tisagenlecleucel, N = 104 [†]	Sheba POC anti CD19, N = 94 [†]
Response at Day 100 Post-CAR-T			
CR	42 (45%)	30 (34%)	10 (18%)
PR	5 (5.3%)	3 (3.4%)	0 (0%)
SD	2 (2.1%)	0 (0%)	0 (0%)
POD	45 (48%)	54 (62%)	45 (82%)
Unknown	38	17	39
Response of CR or PR at Day 100 Post-CAR-T	47 (50%)	33 (38%)	10 (18%)
Unknown	38	17	39
Response of CR at Day 100 Post- CAR-T	42 (45%)	30 (34%)	10 (18%)
Unknown	38	17	39
[†] n (%)			

Abbreviations: complete response (CR), partial response (PR), stable disease (SD), progression of disease (POD).